CAR T-Cell Therapy for Multiple Myeloma: Efficacy & Safety
Advancing CAR T-Cell Therapy: Optimizing Efficacy and Accessibility in Myeloma treatment
Table of Contents
Orlando, FL – The landscape of multiple myeloma treatment is rapidly evolving, with CAR T-cell therapy emerging as a powerful tool. However, maximizing its benefits and ensuring broad patient access remain key priorities. A recent symposium highlighted critical areas for advancement, focusing on maintenance strategies, managing overexpansion, and the optimal sequencing of CAR T-cell therapies with other novel agents like bispecific antibodies.
strategies to Extend CAR T-Cell Therapy Benefits
A significant focus of discussion revolved around strategies to prolong the efficacy of CAR T-cell therapies. This includes exploring maintenance-based approaches that can definitely help CAR T-cells expand and persist, thereby offering a more durable response. Concurrently, the need to prevent overexpansion, which can lead to significant adverse effects, was emphasized. identifying and implementing these nuanced strategies are crucial for optimizing patient outcomes and improving the overall therapeutic window of CAR T-cell treatments.
Key Takeaways from the Symposium
One of the most pressing questions addressed at the symposium was the optimal sequencing of CAR T-cell therapies with bispecific antibodies, especially those targeting BCMA, a common antigen for both modalities. The shared target raises the critical question: “What is the best way to target these things? Is it to do a CAR T-cell therapy first or a bispecific first?”
The symposium highlighted a potential disparity in care within the community setting. Practitioners comfortable offering bispecific antibodies,but lacking the infrastructure for CAR T-cell therapy,may inadvertently be doing a disservice to patients if they do not first evaluate them for CAR T-cell eligibility.
Evidence presented, including data from the phase 2 CARTITUDE-2 trial (NCT04133636), suggests a favorable outcome when CAR T-cell therapy precedes bispecific antibody treatment. Specifically, patients who have responded to CAR T-cell therapy for at least six months appear to have a decent chance of responding well to a subsequent bispecific antibody. Conversely, the efficacy of CAR T-cell therapy may be diminished in patients who have been treated with a bispecific antibody until progression and are then afterward challenged with CAR T-cell therapy.
Based on this emerging data, the prevailing sentiment is that every patient should be offered a CAR T-cell therapy before a bispecific antibody, with limited exceptions. These exceptions might include patients who are exceptionally frail, have significant comorbidities that preclude CAR T-cell therapy, or lack access to a CAR T-cell therapy center.
Hopes for Future Conversations
The overarching hope stemming from this discussion is to ensure that everyone deserves access to CAR T-cell therapy.This translates to a call to action for practitioners to refer patients to specialty centers with CAR T-cell therapy availability. Such referrals are essential for proper evaluation and to determine if a CAR T-cell option is indeed suitable.
For the majority of patients, the answer to CAR T-cell eligibility will be affirmative, and they can expect positive outcomes not only in terms of tolerability but also efficacy – the primary goal for patients seeking treatment. Furthermore, the symposium underscored that while toxicities associated with CAR T-cell therapy exist, they are increasingly manageable as clinical experience grows. This growing understanding and management of toxicities should not serve as a barrier to patients accessing this potentially life-changing treatment.
References
- Paul B. Advances in CAR-T therapy for myeloma. Presented at: 2025 Immune Cell Effector Therapy Symposium; July 26, 2025; Orlando, FL.
- jagannath S, martin TG, Lin Y, et al. Long-term (≥5-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J Clin Oncol. Published online June 3, 2025. doi:10.1200/JCO-25-00760